点击上图▲立即报名 6月19日至6月20日，"生而全球·共融共建"第二届出海全球峰会在新加坡举行。与 会的1300名企业家与20多位来自学界、企业界、海外的嘉宾一起，探讨中国企业出 海的新方向和新路径。 崔洪波老师在论坛上进行了《从中国出发的全球化品牌大航海时代》专题演讲，本文 整理了崔洪波老师演讲的精华部分，分享给大家。 演讲 / 崔洪波 整理 / 巴九灵（微信公众号： 吴晓波频道） 中国公司主导的跨国 经营新时代正在开启 这一轮出海，无疑是一个从中国出发的全球化品牌大航海时代。 中国企业今天的出海，并不是我们要不要出海的问题，而是用何种方式、何种姿势、如何低风险的， 或者说尽可能在一个可控范围内的出海，因 为这是一个时代发展的必然。 今天这么多人来到新加坡出海峰会现场，我觉得很欣慰，一方面是因为大家看到了出海的热度，另一方面是因为大家愿意走出来看看。 "观海"是出海的第一步，企业家要抬头看天，职业经理人要低头走路， 这一点非常重要。当你把生意的界面拉到一个很长的视角时，你的格局和 思维其实已经完全不一样了。 就比如这两年中国的车企，让大家有了很强的民族自豪感，觉得丰田和本田在中国都不行了，我们可以笑傲江湖 ...

Group 1 - The core viewpoint of the news is the release of the "Several Measures to Support the High-Quality Development of Innovative Drugs" by the National Medical Insurance Administration and the National Health Commission, which includes 16 initiatives aimed at supporting the entire chain of innovative drug development, access, and payment [1][2] - The measures emphasize the importance of supporting innovative drugs to go global, encouraging regions to explore building global trading platforms for innovative drugs, particularly targeting Southeast Asia, Central Asia, and other Belt and Road countries [1][5] - The new "1+" drug approval mechanism in Hong Kong, effective from November 2023, aims to streamline the registration process for innovative drugs, allowing for faster market entry and enhancing Hong Kong's role as a bridge for innovative drugs to reach global markets [7][8] Group 2 - The establishment of a commercial health insurance innovative drug directory is a significant highlight of the measures, which will include innovative drugs that exceed basic insurance coverage and have high clinical value [3][4] - The commercial health insurance innovative drug directory will be developed by the National Medical Insurance Administration, allowing companies to apply for inclusion in either the insurance directory or the basic medical insurance directory [3][4] - The measures also aim to enhance the multi-layered payment capabilities for innovative drugs, addressing the challenges of price expectations from innovative drug companies and the payment capabilities of insurance [2][3] Group 3 - The measures propose to support the expansion of investment in innovative drugs by commercial health insurance, fostering a patient capital environment for innovative drug companies [5][6] - The collaboration between Hong Kong and Shenzhen aims to establish a "Real-World Research and Application Center" to promote data sharing and expedite drug approval processes [6][8] - The National Medical Insurance Administration plans to implement more effective measures to support the pricing of innovative drugs going abroad, including exploring stricter price confidentiality mechanisms for drugs in the commercial health insurance directory [10]

Core Insights - In the first half of 2025, 40 Chinese companies successfully listed in the US, raising a total of $871 million, with notable IPOs including Bawang Chaji at $411 million and Ascentage Pharma at $126 million [1][2] Group 1: Market Trends - Nasdaq emerged as the preferred exchange for most companies, with 39 out of 40 listings occurring there [2] - The number of IPOs increased by 44% year-on-year, primarily driven by small and medium-sized enterprises, although the overall fundraising amount decreased by 62% due to a lack of large IPOs [2] - The average fundraising amount for companies going public was generally small, with most raising between $5 million and $15 million [2] Group 2: Company Performances - Bawang Chaji became the first Chinese tea drink company to list in the US, pricing its shares at $28 and issuing 14.68 million American Depositary Shares (ADS) [2] - As of March 31, 2025, Bawang Chaji reported a total of 6,681 global stores, a quarterly GMV of 8.23 billion yuan, total net revenue of 3.39 billion yuan (up 35.4% year-on-year), and a net profit of 677 million yuan (up 13.8% year-on-year) [3] - Ascentage Pharma, which focuses on developing therapies for cancer and hepatitis B, saw its stock price increase by 128.26% post-IPO [3] Group 3: Notable IPOs and Market Reactions - Huatai Financial, listed on April 1, 2025, experienced a remarkable first-day surge of 396.25% [4] - Other companies like DIGINEX, Jian Yong Biotechnology, and Lingzhang Portal also saw first-day gains exceeding 20% [5] - A total of 8 companies had stock prices that increased by over 100% after their IPOs, including DIGINEX, Lingzhang Portal, and Ascentage Pharma [5]

Core Insights - The article discusses the recent measures introduced by the National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) to support the development of innovative drugs in China, focusing on policy support and pricing guarantees for companies while ensuring accessibility and safety for the public [1][2]. Group 1: Policy Measures - The "Several Measures to Support the High-Quality Development of Innovative Drugs" includes 16 measures across five areas, addressing the entire chain of innovative drug development, approval, hospital use, and multi-channel payment [1]. - The NHSA has made significant progress in the approval of innovative drugs, with the number of Class 1 innovative drugs approved reaching 48 in 2024, over five times the number in 2018, and nearly 40 already in the first half of this year [1]. Group 2: Multi-Payment System - The NHSA is establishing a multi-payment system for innovative drugs, which includes regular adjustments to the medical insurance drug list and the introduction of a commercial health insurance innovative drug list [2][3]. - The commercial health insurance innovative drug list will focus on highly innovative drugs with significant clinical value that exceed the basic medical insurance coverage, enhancing the multi-layered medical security system [2]. Group 3: Market Dynamics - The commercial health insurance market in China has been growing rapidly, with the original insurance premium income for commercial health insurance reaching 977.3 billion yuan in 2024, a year-on-year increase of 8.2% [3]. - The NHSA aims to streamline the application process for innovative drugs to be included in both the medical insurance and commercial health insurance lists, reducing the administrative burden on companies [3][4]. Group 4: Support for Global Expansion - The measures also aim to support the global market development of Chinese innovative drugs, with over 90 overseas licensing transactions completed by Chinese pharmaceutical companies in 2024, totaling over 50 billion USD [6]. - The NHSA will facilitate the entry of domestic drugs into ASEAN countries and support innovative drugs in overseas markets, including the implementation of price confidentiality for certain drugs [6][7].

凤凰网财经讯 6月28-29日，"2025中国企业出海高峰论坛"在深圳举行，本次论坛由凤凰网主 办，雪花超高端系列品牌-醴首席赞助合作，中国企业出海全球化理事会联合主办，以"为开放的世 界"为主题，旨在全球产业链深度重构之际，为中国企业搭建思想碰撞、资源对接、规则对话的高 端平台，系统性破解出海难题，共探生态共赢转型路径。 胡捷观察到，中国企业的"杀手"是第二个中国人，很多中国企业不管在国内还是国外，最后都杀得 片甲不留，大家虽然产能很大但是没有利润。想要解决这一问题，需要企业自律、协同与平衡，因 而需要所有企业家共同去努力。 点击 " 阅读原文 " 了解更多详情 ！ 上海交通大学上海高级金融学院实践教授胡捷出席了论坛，并发表主题为《软实力，高质量出海的 硬道理》的演讲，其中对百年大变局与全球化2.0的背景、关税战及其对企业出海的影响、国际产业 链格局重构下中国企业的应对之策以及软实力建设展开了深入探讨。 在谈到可持续发展时，胡捷表示中国企业要规避行业风险，比如恶性竞争。胡捷提及自己经常问企 业家，"你出海怕这个竞争对手吗？他说我不怕，但是我怕第二个中国人来。" 上海交通大学上海高级金融学院实践教授胡捷 ...

点击 " 阅读原文 " 了解更多详情 ！ 储殷表示，"卷"是市场经济的必然规律，真正想缓解这一现象，需要依赖市场外的制度设计，比如 强制八小时工作制和为加班付费。在他看来，随着90后、00后逐渐成为市场经济主体，中国社会将 不会那么卷，因为70后、80后这两代人普遍很难接受不工作，"不让他上班，他着急"。 他以当年遇到富士康工人堵路抗议"不让加班"为例，他感叹，这代人更愿意为挣钱牺牲健康。储殷 表示，高强度的工作是违反人类生物规律的，随着新一代成为主体，以及经济继续发展壮大，这一 状况将自然缓解，一切需要"留给时间"。 凤凰网财经讯6月28-29日，"2025中国企业出海高峰论坛"在深圳举行，本次论坛由凤凰网主办， 雪花超高端系列品牌-醴首席赞助合作，中国企业出海全球化理事会联合主办，以"为开放的世 界"为主题，旨在全球产业链深度重构之际，为中国企业搭建思想碰撞、资源对接、规则对话的高 端平台，系统性破解出海难题，共探生态共赢转型路径。 在闭幕对话环节，全球化智库(CCG)副主任、苏州大学讲席教授高志凯和盘古智库研究员、演说家 冠军储殷针对企业出海也内卷的现象展开了讨论。 ...

Core Viewpoint - Luckin Coffee has officially opened its first two stores in New York City, marking its entry into the U.S. market after five years of absence from Nasdaq. The company aims to attract a diverse customer base by strategically selecting locations in busy, multicultural areas rather than predominantly Chinese neighborhoods [2][5]. Group 1: Store Opening and Promotions - On June 30, 2025, Luckin Coffee opened its first two stores in New York, located at 755 Broadway and 800 Sixth Avenue, offering a promotional price of $1.99 for orders made through its official app [2]. - Prior to the official opening, Luckin conducted four pop-up events in high-traffic areas of New York City to promote its app and engage with potential customers [3]. Group 2: Marketing Strategy - The pop-up events were designed to encourage app downloads, with incentives such as free coffee and a chance to win a year of free coffee, successfully attracting a large crowd despite the heat [3]. - The company employed a diverse group of volunteers to help engage local consumers, with a significant portion of attendees being Chinese students and workers [4]. Group 3: Location Strategy - Luckin's choice of locations reflects its commitment to penetrating the U.S. market, focusing on areas with stable foot traffic rather than high-rent shopping centers [5][7]. - The two stores are situated in B+ grade locations, balancing cost and customer flow, indicating Luckin's confidence in its brand positioning and operational capabilities [7]. Group 4: Market Context - The U.S. coffee market is substantial, generating nearly $85 billion in revenue in 2023, with Americans consuming approximately 400 million cups of coffee daily [8]. - The competitive landscape in New York is intense, with numerous established coffee brands, including Starbucks, dominating the market [7][8]. Group 5: Challenges and Considerations - Luckin faces challenges in adapting its pricing strategy to the U.S. market, where its original pricing may not be competitive compared to local brands [9][10]. - The company must navigate local regulations, such as the prohibition of cashless businesses in New York, which could impact its app-based ordering model [14].

■ 区域市场格局：全球市场呈现"核心稳量、新兴增量"格局。 美日韩三大传统市场贡献57.27%收入，但增速 分化（韩国增长快，美国停滞）。欧洲以245亿欧元规模成为"第四极"市场。东南亚（庞大用户基数）、中东 （超高付费力，沙特ARPPU达270美元）、拉美（休闲游戏蓝海）构成重要的新兴增量市场。这促使企业分层 布局，头部深耕欧美，中小团队开拓新兴市场。 ■ 发展历程与市场规模： 国产游戏出海经历了四个关键阶段：2012年前端游试水东南亚（如剑侠情缘）； 2012-2018年SLG手游爆发（如列王的纷争）；2018年后进入全品类时代（如原神）；2024年标志性3A大作 （黑神话悟空）引领文化出海新阶段。 2024年，中国自研游戏海外收入达185.57亿美元，占全球市场份额约 11%，展现出强劲增长势头。 ■ 硬件生态与文化偏好： 中国手游占比（73.13%）远高于全球水平（52.25%），导致目前国产游戏出海仍以 移动游戏为主，未来在主机游戏领域或存在深耕机遇。游戏类型偏好深受区域文化影响：美国博彩类领先 （28.9%流水），欧洲偏好SLG（33.7%），日本RPG主导（52%份额）。消除类和策略类凭借普适性 ...

根据海关总署数据，今年前五个月，国内进出口总值17.94万亿，其中出口增长7.2%，进口下降3.8%。 与此同时，5月单月出口增长6.3%，但以美元计价的商品增速环比减缓至4.8%。与此同时，东盟继续跃 升为中国最大的贸易伙伴，外贸占比高达16.8%。 从大航海时代到二次工业革命，美国经济腾飞，到新世纪的全球化分工，每个经济全球化的关键节点， 背后往往伴随着全球物流体系的深层次变革。 "关税博弈下，传统物流通道正在面临着严重的严峻的挑战……由于传统物流通道被美国等一些国家控 制，我国正加速建设新型的，多元化国际物流通道。"近日，中国集装箱行业协会副秘书长郝攀峰在第 五届中国罐式集装箱合作发展暨化工与液态食品物流技术应用大会上表示。 郝攀峰认为，目前中国凭借完整的供应链和中间品的优势，保持着全球供应链的核心地位。而随着国际 经贸结构的深层次变化，东盟成为了中国产业全球分工合作的新落脚点受到大量的关注，中间品贸易的 物流能力，以及全新物流通道的开辟等，也亟需补齐短板。 与东盟产业合作进入第三阶段 郝攀峰指出，目前亚洲发展中国家成为全球直接投资(FDI)的主要流入目的地，占比约达四成。其中中 国、东盟又占到亚洲FD ...

【大河财立方 记者 王鑫】7月1日，创新药板块高开高走。 招商证券表示，中国创新药登上全球竞争舞台，技术创新+市场扩容引领创新药产业趋势行情，持续看好后续催 化与兑现。该券商指出，创新药出海，是供给与需求方相互成就的产业逻辑。截至目前，2025年国内创新药项 目已经完成BD项目数量超过80项，分子形式多样广泛。从MNCs引进交易数量及交易金额情况来看，中国成为 增长最快的国家。国内创新药企从2020～2024年首付款金额从5亿美元增长至41亿美元，也侧面印证了国内药企 的全球竞争力。 国联民生证券认为，创新药或将逐步进入兑现期。2025年预计是国内创新药授权出海的重要年份，自2018 年"4+7"集采以后，国内企业纷纷开始从仿制药向创新药转型，至今7年时间，已经陆续进入兑现期。部分先驱 创新药企业有望陆续实现盈亏平衡，利润端转正。 责编:史健 | 审校:张翼鹏 | 审核:李震 | 监审:古筝 截至收盘，Wind创新药指数上涨3.46%。从个股来看，前沿生物涨停，舒泰神、科兴制药涨逾15%，荣昌生物、 微芯生物涨超10%，华纳药厂、泽璟制药、千红制药等涨幅居前。 | 序号 名称 | | 现价 | 涨跌幅 ▼ | ...